UB Paderborn / Katalog / Suche / in CDI

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

British journal of cancer, 2008-01, Vol.98 (2), p.502-507

2008

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of RAD51 occurs in aggressive prostatic cancer

Histopathology, 2009-12, Vol.55 (6), p.696-704

2009

Link zum Volltext

Verfügbarkeit prüfen

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

Breast cancer research : BCR, 2023-06, Vol.25 (1), p.72-72, Article 72

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1558-1558

2017

Link zum Volltext

Verfügbarkeit prüfen

Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1866-1872

2006

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Nature communications, 2019-04, Vol.10 (1), p.1741-18, Article 1741

2019

Link zum Volltext

Verfügbarkeit prüfen

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Nature genetics, 2020-01, Vol.52 (1), p.56-73

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (3), p.624-638

2020

Link zum Volltext

Verfügbarkeit prüfen

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Genetics in medicine, 2021-09, Vol.23 (9), p.1726-1737

2021

Link zum Volltext

Verfügbarkeit prüfen

Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers

Oncology reports, 2010-02, Vol.23 (2), p.299-305

2010

Link zum Volltext

Verfügbarkeit prüfen

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Genetics in medicine, 2020-10, Vol.22 (10), p.1653-1666

2020

Link zum Volltext

Verfügbarkeit prüfen

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

Genetic epidemiology, 2020-07, Vol.44 (5), p.442-468

2020

Link zum Volltext

Verfügbarkeit prüfen

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

British journal of cancer, 2019-07, Vol.121 (2), p.180-192

2019

Link zum Volltext

Verfügbarkeit prüfen

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

European journal of human genetics : EJHG, 2022-03, Vol.30 (3), p.349-362

2022

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Nature communications, 2021-05, Vol.12 (1), p.2986-2, Article 2986

2021

Link zum Volltext

Verfügbarkeit prüfen

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

JNCI : Journal of the National Cancer Institute, 2022-01, Vol.114 (1), p.109-122

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

European journal of human genetics : EJHG, 2022-05, Vol.30 (5), p.630-631

2022

Link zum Volltext

Verfügbarkeit prüfen

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

American journal of obstetrics and gynecology, 2021-07, Vol.225 (1), p.51.e1-51.e17

2021

Link zum Volltext

Verfügbarkeit prüfen

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

Communications biology, 2022-10, Vol.5 (1), p.1061-1061, Article 1061

2022

Link zum Volltext

Verfügbarkeit prüfen

BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1545-1545

2012

Link zum Volltext

Verfügbarkeit prüfen

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Breast cancer research : BCR, 2012-02, Vol.14 (1), p.R33-R33

2012

Link zum Volltext

Verfügbarkeit prüfen

The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers

Breast cancer research : BCR, 2005-01, Vol.7 (2), p.R176-R183

2005

Link zum Volltext

Verfügbarkeit prüfen

No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

Breast cancer research and treatment, 2009-05, Vol.115 (2), p.307-313

2009

Link zum Volltext

Verfügbarkeit prüfen

Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.29-29

2013

Link zum Volltext

Verfügbarkeit prüfen

Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS)

Breast cancer research : BCR, 2005-01, Vol.7 (S2), p.P1-P1, Article P1.08

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

Overexpression of RAD51 occurs in aggressive prostatic cancer

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study

Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers

No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer

Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS)

Suchergebnisse filtern